Lihong Qu

No. 150, Jimo Road
Pudong, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A machine learning-based predictive model for 48-week hepatitis B surface antigen seroclearance in chronic hepatitis B patients treated with pegylated interferon α-2b: prediction at week 24.

A machine learning-based predictive model for 48-week hepatitis B surface antigen seroclearance in chronic hepatitis B patients treated with pegylated interferon α-2b: prediction at week 24.

Journal: Frontiers in cell and developmental biology

Published: October 29, 2025

Community-based interventions for hepatitis C virus elimination among people who use drugs in Shanghai, China.

Community-based interventions for hepatitis C virus elimination among people who use drugs in Shanghai, China.

Journal: Harm reduction journal

Published: October 13, 2025

Development of a diagnostic model for MASLD and identification of daidzein as the potential drug using bioinformatics analysis and experiments.

Development of a diagnostic model for MASLD and identification of daidzein as the potential drug using bioinformatics analysis and experiments.

Journal: Frontiers in immunology

Published: September 04, 2025

Interim Analysis of 48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study.

Interim Analysis of 48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study.

Journal: Journal of clinical and translational hepatology

Published: April 15, 2025

Corrigendum to "Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial" [Clin Microbiol Infect 31 (2025) 274-281].

Corrigendum to "Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial" [Clin Microbiol Infect 31 (2025) 274-281].

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: February 12, 2025

Oral ADC189 for adults and adolescents with uncomplicated influenza.

Oral ADC189 for adults and adolescents with uncomplicated influenza.

Journal: The Journal of infection

Published: November 10, 2024

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks.

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks.

Journal: Hepatology international

Published: September 13, 2024

Construction of a prognostic model based on disulfidptosis-related genes and identification of CCNA2 as a novel biomarker for hepatocellular carcinoma.

Construction of a prognostic model based on disulfidptosis-related genes and identification of CCNA2 as a novel biomarker for hepatocellular carcinoma.

Journal: Biology direct

Published: September 03, 2024

Factors and machine learning models for predicting successful discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury: a retrospective cohort study based on MIMIC-IV database.

Factors and machine learning models for predicting successful discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury: a retrospective cohort study based on MIMIC-IV database.

Journal: BMC nephrology

Published: August 25, 2024

Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial.

Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: July 03, 2024

Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study.

Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study.

Journal: Frontiers in microbiology

Published: May 05, 2024

Alterations of pathogen transmission patterns and attenuated immune stimulation might be the cause of increased adult respiratory infections cases in 2023, results from a multi-center study in mainland China.

Alterations of pathogen transmission patterns and attenuated immune stimulation might be the cause of increased adult respiratory infections cases in 2023, results from a multi-center study in mainland China.

Journal: Heliyon

Published: February 20, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026